Julia MV
@julialmv.bsky.social
Long COVID patient-researcher
@ Scripps Research & Patient-Led Research Collaborative
@ Scripps Research & Patient-Led Research Collaborative
Pinned
The Long COVID Treatment Trial – Tirzepatide (LoCITT-T) is now open for enrollment for people with Long COVID in all states but Hawaii (due to concerns about maintaining temperature control in shipping), DC, and PR:
longcovid.scripps.edu/locitt-t/?ut...
longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
baby just posted his second ever tiktok! trying to spread the word about the @julialmv.bsky.social's amazing clinical trial.
www.tiktok.com/t/ZTr2Rnwry/
if you are a tiktok user could you like and engage so it gets picked up? let's get this trial fully enrolled in record time!
www.tiktok.com/t/ZTr2Rnwry/
if you are a tiktok user could you like and engage so it gets picked up? let's get this trial fully enrolled in record time!
What questions do YOU have about this Long COVID clinical trial? @Scripps Research #longcovid #longcovidadvocacy #longcovidtreatments #clinicaltrials #chronicillness
TikTok video by Ezra
www.tiktok.com
November 25, 2025 at 9:53 PM
baby just posted his second ever tiktok! trying to spread the word about the @julialmv.bsky.social's amazing clinical trial.
www.tiktok.com/t/ZTr2Rnwry/
if you are a tiktok user could you like and engage so it gets picked up? let's get this trial fully enrolled in record time!
www.tiktok.com/t/ZTr2Rnwry/
if you are a tiktok user could you like and engage so it gets picked up? let's get this trial fully enrolled in record time!
Reposted by Julia MV
We've enrolled more than 700 participants (of 1,000 planned) in 3 weeks to a randomized trial for treatment of #LongCovid
Founder and director of the Scripps Research Translational Institute, @erictopol.bsky.social, and Julia Moore Vogel, co–principal investigator of the Long COVID Treatment Trial, were featured in @wired.com, sharing insights on a nationwide study testing GLP-1s for long COVID.
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
ow.ly
November 23, 2025 at 7:09 PM
We've enrolled more than 700 participants (of 1,000 planned) in 3 weeks to a randomized trial for treatment of #LongCovid
We are up to 688 LoCITT participants!
If we could enroll all 1,000 participants within a month of launch (by 11/30), it would send a powerful message about the demand for remote Long COVID clinical trials.
We appreciate the community's help to spread the word:
longcovid.scripps.edu/locitt-t/?ut...
If we could enroll all 1,000 participants within a month of launch (by 11/30), it would send a powerful message about the demand for remote Long COVID clinical trials.
We appreciate the community's help to spread the word:
longcovid.scripps.edu/locitt-t/?ut...
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 21, 2025 at 7:59 PM
We are up to 688 LoCITT participants!
If we could enroll all 1,000 participants within a month of launch (by 11/30), it would send a powerful message about the demand for remote Long COVID clinical trials.
We appreciate the community's help to spread the word:
longcovid.scripps.edu/locitt-t/?ut...
If we could enroll all 1,000 participants within a month of launch (by 11/30), it would send a powerful message about the demand for remote Long COVID clinical trials.
We appreciate the community's help to spread the word:
longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
A few charts we created for this analysis.
November 21, 2025 at 2:33 PM
A few charts we created for this analysis.
Reposted by Julia MV
Not knowing about PEM is proof positive you don't know IACCs.
Even if you're not studying #MECFS, omitting the possibility of PEM in a trial for #LongCOVID (where many meet criteria for #MECFS) or for common comorbidities, like fibro, hypermobility disorders like #EDS, or #POTS is in error.
Even if you're not studying #MECFS, omitting the possibility of PEM in a trial for #LongCOVID (where many meet criteria for #MECFS) or for common comorbidities, like fibro, hypermobility disorders like #EDS, or #POTS is in error.
November 21, 2025 at 3:56 PM
Not knowing about PEM is proof positive you don't know IACCs.
Even if you're not studying #MECFS, omitting the possibility of PEM in a trial for #LongCOVID (where many meet criteria for #MECFS) or for common comorbidities, like fibro, hypermobility disorders like #EDS, or #POTS is in error.
Even if you're not studying #MECFS, omitting the possibility of PEM in a trial for #LongCOVID (where many meet criteria for #MECFS) or for common comorbidities, like fibro, hypermobility disorders like #EDS, or #POTS is in error.
I've been surprised to see how many Long COVID trials focus on exercise & how few measure PEM.
Thanks to @spichaksimon.bsky.social for covering this in @thesicktimes.org
"Testing exercise is “money down the drain” & won’t advance understanding of LC, experts say"
thesicktimes.org/2025/11/21/l...
Thanks to @spichaksimon.bsky.social for covering this in @thesicktimes.org
"Testing exercise is “money down the drain” & won’t advance understanding of LC, experts say"
thesicktimes.org/2025/11/21/l...
Less than 20% of Long COVID trials involving exercise even mention post-exertional malaise - The Sick Times
An analysis by The Sick Times find that less than 15% of Long COVID clinical trials testing the benefits of exercise or cardiopulmonary rehabilitation measured post-exertional malaise, according to th...
thesicktimes.org
November 21, 2025 at 4:47 PM
I've been surprised to see how many Long COVID trials focus on exercise & how few measure PEM.
Thanks to @spichaksimon.bsky.social for covering this in @thesicktimes.org
"Testing exercise is “money down the drain” & won’t advance understanding of LC, experts say"
thesicktimes.org/2025/11/21/l...
Thanks to @spichaksimon.bsky.social for covering this in @thesicktimes.org
"Testing exercise is “money down the drain” & won’t advance understanding of LC, experts say"
thesicktimes.org/2025/11/21/l...
Reposted by Julia MV
Wanna see a visual on the result of the Republican attack on public health?
I’ve got you covered. This is from Pew Research Center’s most recent survey, showing a 27% drop in Republican support for school vaccine requirements from 2016-2025.
I’ve got you covered. This is from Pew Research Center’s most recent survey, showing a 27% drop in Republican support for school vaccine requirements from 2016-2025.
November 20, 2025 at 8:34 PM
Wanna see a visual on the result of the Republican attack on public health?
I’ve got you covered. This is from Pew Research Center’s most recent survey, showing a 27% drop in Republican support for school vaccine requirements from 2016-2025.
I’ve got you covered. This is from Pew Research Center’s most recent survey, showing a 27% drop in Republican support for school vaccine requirements from 2016-2025.
Reposted by Julia MV
We are witnessing a poisonous effort to destroy what the vast majority of Americans know is a key pillar of public health.
Vaccines are responsible for 40% of the reduction in child mortality achieved in the last half century.
Vaccines are responsible for 40% of the reduction in child mortality achieved in the last half century.
November 20, 2025 at 6:23 PM
We are witnessing a poisonous effort to destroy what the vast majority of Americans know is a key pillar of public health.
Vaccines are responsible for 40% of the reduction in child mortality achieved in the last half century.
Vaccines are responsible for 40% of the reduction in child mortality achieved in the last half century.
Reposted by Julia MV
If you're over legacy media, I've got great news! You can donate to our non-profit newsroom at @thesicktimes.org to help us keep investigating injustices, challenging powerful institutions, and offering a platform for those affected by the #LongCOVID crisis. the-sick-times.fundjournalism.org/donate/
November 20, 2025 at 4:44 PM
If you're over legacy media, I've got great news! You can donate to our non-profit newsroom at @thesicktimes.org to help us keep investigating injustices, challenging powerful institutions, and offering a platform for those affected by the #LongCOVID crisis. the-sick-times.fundjournalism.org/donate/
Great to see this meta-analysis in BMJ:
"Decentralised trials provide similar answers to clinical questions as traditional, non-decentralised randomised trials.
They do not systematically overestimate or underestimate effect estimates, ..."
www.bmj.com/content/391/...
1/2
"Decentralised trials provide similar answers to clinical questions as traditional, non-decentralised randomised trials.
They do not systematically overestimate or underestimate effect estimates, ..."
www.bmj.com/content/391/...
1/2
Agreement of treatment effects in decentralised trials versus traditional trials: meta-epidemiological study
Objective To compare treatment effects from trials designed as decentralised trials or as traditional non-decentralised trials.
Design Meta-epidemiological study.
Data source PubMed database.
Eligi...
www.bmj.com
November 18, 2025 at 6:48 PM
Great to see this meta-analysis in BMJ:
"Decentralised trials provide similar answers to clinical questions as traditional, non-decentralised randomised trials.
They do not systematically overestimate or underestimate effect estimates, ..."
www.bmj.com/content/391/...
1/2
"Decentralised trials provide similar answers to clinical questions as traditional, non-decentralised randomised trials.
They do not systematically overestimate or underestimate effect estimates, ..."
www.bmj.com/content/391/...
1/2
Reposted by Julia MV
In decades to come, we will look back at 2025 - following the most devastating pandemic in a century - as the year we turned back hard-earned progress on combating infectious diseases.
That means the comeback of preventable diseases. And the emergence of new ones.
www.science.org/content/arti...
That means the comeback of preventable diseases. And the emergence of new ones.
www.science.org/content/arti...
The Trump administration is dismantling efforts to fight the next pandemic
A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn
www.science.org
November 13, 2025 at 10:06 PM
In decades to come, we will look back at 2025 - following the most devastating pandemic in a century - as the year we turned back hard-earned progress on combating infectious diseases.
That means the comeback of preventable diseases. And the emergence of new ones.
www.science.org/content/arti...
That means the comeback of preventable diseases. And the emergence of new ones.
www.science.org/content/arti...
Reposted by Julia MV
The new approach is essentially to stick your head in the sand and go to the gym as a model for pandemic preparedness.
Suffice to say, such a model will not work, but I don't want to belabor the point - I have made it many times already. E.g., here:
bsky.app/profile/kgan...
Suffice to say, such a model will not work, but I don't want to belabor the point - I have made it many times already. E.g., here:
bsky.app/profile/kgan...
I recently gave a talk at Cornell and sat down with Dr. Leifer for her "Immune" podcast. I really enjoyed our wide-ranging conversation, from how I got started in science, how immunity shapes evolution, pandemic risk, and, the current state of US science.
🎧👇
podcasts.apple.com/us/podcast/v...
🎧👇
podcasts.apple.com/us/podcast/v...
Virus-immune Tug-of-war with Kristian Andersen
Podcast Episode · Immune · 11/11/2025 · 1h
podcasts.apple.com
November 14, 2025 at 5:58 PM
The new approach is essentially to stick your head in the sand and go to the gym as a model for pandemic preparedness.
Suffice to say, such a model will not work, but I don't want to belabor the point - I have made it many times already. E.g., here:
bsky.app/profile/kgan...
Suffice to say, such a model will not work, but I don't want to belabor the point - I have made it many times already. E.g., here:
bsky.app/profile/kgan...
Congrats Eric - what a well-deserved honor!
“I never lose my optimism about advances in bio medicine and in the practice of medicine,” he says. Even if there are efforts to suppress that work, if it’s important enough, scientists will pursue it. “We just have to figure out a path to get it done.”
“I never lose my optimism about advances in bio medicine and in the practice of medicine,” he says. Even if there are efforts to suppress that work, if it’s important enough, scientists will pursue it. “We just have to figure out a path to get it done.”
Grateful to @usnews.com for recognition as one of 25 best leaders for 2025
usnews.com/news/best-le...
Profile usnews.com/news/leaders...
usnews.com/news/best-le...
Profile usnews.com/news/leaders...
November 17, 2025 at 5:00 PM
Congrats Eric - what a well-deserved honor!
“I never lose my optimism about advances in bio medicine and in the practice of medicine,” he says. Even if there are efforts to suppress that work, if it’s important enough, scientists will pursue it. “We just have to figure out a path to get it done.”
“I never lose my optimism about advances in bio medicine and in the practice of medicine,” he says. Even if there are efforts to suppress that work, if it’s important enough, scientists will pursue it. “We just have to figure out a path to get it done.”
If you're not devastated by this news, please read some of Alice's work.
She was a champion for justice, lifting the voices of a broad array of disabled people, and disabled joy ❤️
disabilityvisibilityproject.com/book/
She was a champion for justice, lifting the voices of a broad array of disabled people, and disabled joy ❤️
disabilityvisibilityproject.com/book/
November 17, 2025 at 4:00 PM
If you're not devastated by this news, please read some of Alice's work.
She was a champion for justice, lifting the voices of a broad array of disabled people, and disabled joy ❤️
disabilityvisibilityproject.com/book/
She was a champion for justice, lifting the voices of a broad array of disabled people, and disabled joy ❤️
disabilityvisibilityproject.com/book/
It is such a joy to share this trial with the Long COVID community!
We know the second 500 will be tougher to recruit & we'd love your help to finish enrollment quickly with as much diversity as possible
longcovid.scripps.edu/locitt-t/?ut...
We know the second 500 will be tougher to recruit & we'd love your help to finish enrollment quickly with as much diversity as possible
longcovid.scripps.edu/locitt-t/?ut...
November 17, 2025 at 3:57 PM
It is such a joy to share this trial with the Long COVID community!
We know the second 500 will be tougher to recruit & we'd love your help to finish enrollment quickly with as much diversity as possible
longcovid.scripps.edu/locitt-t/?ut...
We know the second 500 will be tougher to recruit & we'd love your help to finish enrollment quickly with as much diversity as possible
longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
The Scripps tirzepatide trial is in @wired.com today! Thanks so much for covering this @emilymullin.bsky.social!
The signup link for the trial: longcovid.scripps.edu/locitt-t/?ut...
The signup link for the trial: longcovid.scripps.edu/locitt-t/?ut...
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
www.wired.com
November 14, 2025 at 7:30 PM
The Scripps tirzepatide trial is in @wired.com today! Thanks so much for covering this @emilymullin.bsky.social!
The signup link for the trial: longcovid.scripps.edu/locitt-t/?ut...
The signup link for the trial: longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of #LongCovid. @wired.com @emilymullin.bsky.social
www.wired.com/story/weight...
www.wired.com/story/weight...
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
www.wired.com
November 14, 2025 at 6:22 PM
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of #LongCovid. @wired.com @emilymullin.bsky.social
www.wired.com/story/weight...
www.wired.com/story/weight...
LoCITT-T trial was covered by Wired today:
www.wired.com/story/weight...
My comments include:
"For the long Covid population...if you’re requiring people to come into a clinic, you’re systematically excluding the most severely affected folks who are housebound or bedbound."
www.wired.com/story/weight...
My comments include:
"For the long Covid population...if you’re requiring people to come into a clinic, you’re systematically excluding the most severely affected folks who are housebound or bedbound."
Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
www.wired.com
November 14, 2025 at 6:23 PM
LoCITT-T trial was covered by Wired today:
www.wired.com/story/weight...
My comments include:
"For the long Covid population...if you’re requiring people to come into a clinic, you’re systematically excluding the most severely affected folks who are housebound or bedbound."
www.wired.com/story/weight...
My comments include:
"For the long Covid population...if you’re requiring people to come into a clinic, you’re systematically excluding the most severely affected folks who are housebound or bedbound."
I just had the thought "we're half way there"
And now I will have Bon Jovi in my head for the foreseeable future
Send prayers (yes that's a joke)
And now I will have Bon Jovi in my head for the foreseeable future
Send prayers (yes that's a joke)
Our randomized, placebo-controlled trial of tirzepatide (Zepbound) for #LongCovid has already enrolled 500 participants of 1000 planned in less than 2 weeks!
longcovid.scripps.edu/locitt-t/
longcovid.scripps.edu/locitt-t/
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 14, 2025 at 4:00 PM
I just had the thought "we're half way there"
And now I will have Bon Jovi in my head for the foreseeable future
Send prayers (yes that's a joke)
And now I will have Bon Jovi in my head for the foreseeable future
Send prayers (yes that's a joke)
Reposted by Julia MV
Please spread the word about this exciting #LongCovid trial that they’ve made super easy to participate in from home! The faster they get enough participants, the faster they can release results
There are LoCITT-T participants across 46 states & DC!
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 13, 2025 at 1:34 AM
Please spread the word about this exciting #LongCovid trial that they’ve made super easy to participate in from home! The faster they get enough participants, the faster they can release results
This was a fun one - we talked through each step of my career from grad school to LoCITT-T, as well as my hope for the future of accessibility & inclusion in clinical trials & health research.
Progress, Potential, and Possibilities: 'Dr. Julia Moore Vogel - Scripps Research - Visionary, Patient-Centric Health Research For All'
'..Vogel..Assistant Professor & Senior Program Director at Scripps Research..including The Long COVID Treatment Trial..'
www.youtube.com/watch?v=iH_j...
'..Vogel..Assistant Professor & Senior Program Director at Scripps Research..including The Long COVID Treatment Trial..'
www.youtube.com/watch?v=iH_j...
Dr. Julia Moore Vogel - Scripps Research - Visionary, Patient-Centric Health Research For All
YouTube video by Progress, Potential, and Possibilities
www.youtube.com
November 13, 2025 at 5:01 PM
This was a fun one - we talked through each step of my career from grad school to LoCITT-T, as well as my hope for the future of accessibility & inclusion in clinical trials & health research.
Reposted by Julia MV
Our randomized, placebo-controlled trial of tirzepatide (Zepbound) for #LongCovid has already enrolled 500 participants of 1000 planned in less than 2 weeks!
longcovid.scripps.edu/locitt-t/
longcovid.scripps.edu/locitt-t/
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 13, 2025 at 3:21 PM
Our randomized, placebo-controlled trial of tirzepatide (Zepbound) for #LongCovid has already enrolled 500 participants of 1000 planned in less than 2 weeks!
longcovid.scripps.edu/locitt-t/
longcovid.scripps.edu/locitt-t/
There are LoCITT-T participants across 46 states & DC!
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
longcovid.scripps.edu
November 12, 2025 at 6:46 PM
There are LoCITT-T participants across 46 states & DC!
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
We currently do not have participants from:
North Dakota
South Dakota
Mississippi
Puerto Rico
Can you spread the word to anyone with LC there (or in any other, more generally underrepresented community):
longcovid.scripps.edu/locitt-t/?ut...
Reposted by Julia MV
Many Long COVID trials have reported negative results in 2024 and 2025. In our Comment for @thelancetinfdis.bsky.social we argue that inadequate outcome measures might have played a role. (1/12)
November 8, 2025 at 12:08 AM
Many Long COVID trials have reported negative results in 2024 and 2025. In our Comment for @thelancetinfdis.bsky.social we argue that inadequate outcome measures might have played a role. (1/12)
Reposted by Julia MV
I really do think The Sick Times is doing some of the most important journalism of our generation. And I can tell you firsthand that Miles and Betsy are the real deal. They care so, so much about getting it right. They’re incredible humans in addition to being such good journalists.
Our #LongCOVID journalism requires reader support — with your help, we can prepare our non-profit newsroom for whatever 2026 brings.
Will you donate today and help us keep this vital work going? the-sick-times.fundjournalism.org/donate/
Will you donate today and help us keep this vital work going? the-sick-times.fundjournalism.org/donate/
November 7, 2025 at 8:50 PM
I really do think The Sick Times is doing some of the most important journalism of our generation. And I can tell you firsthand that Miles and Betsy are the real deal. They care so, so much about getting it right. They’re incredible humans in addition to being such good journalists.